This proposal is a collaborative venture from the Davidson and Kretzler laboratories that reflects a set of converging experiments based on gene discovery in human and murine SLE nephritis, and a set of functional studies in mice based on hypotheses generated as a result of these studies. The proposal is based on the central hypothesis that molecular markers of SLE nephritis progression pathways can serve as predictors of outcome and therapeutic response. Using a unique model of remission induction of murine SLE nephritis we have identified two main physiologic pathways are associated disease onset and remission. These are: 1) activation of the renal endothelium and 2) activation of renal macrophages and dendritic cells with production of pro-inflammatory cytokines. Part of the signature is shared with other progressive murine renal diseases and both signatures overlap significantly with those found in human SLE renal biopsies. We have further discovered that activation of resident renal macrophages is a hallmark of onset of clinical nephritis in several disparate murine SLE models and is associated with upregulation of ITGAM, a gene that has recently been found to confer SLE risk. The current proposal focuses on the activation pathways of macrophages/dendritic cells in the kidneys with a view to identifying key pathways that could be targeted therapeutically. We will first determine the phenotype and origins of activated macrophages/monocytes in murine lupus kidneys and whether their precursors can be found in the peripheral blood. We will then characterize the function of activated macrophages and dendritic cells in the kidneys and urine sediment. We will use a combination of immuno- histochemistry, flow cytometry, functional studies and gene expression profiling to identify genes that are putative severity/prognostic markers or that are biomarkers for disease onset, remission and relapse. Parallel studies in human SLE renal biopsies and urinary cell pellets will allow us to identify pathways that can further be explored functionally in the murine models. At the same time candidate genes identified in the murine models will be evaluated in the human samples using a costume array qRT-PCR approach. More sophisticated systems based analysis of the human and murine data sets will help identify key signal transduction and transcriptional pathways that can be targeted therapeutically. Our studies allow us to make maximal use of large data sets to hone in on pathways that are likely to be shared among SLE patients. In addition we plan to build our consortium for standardized state-of-the-art tissue procurement and banking and to make data available through sophisticated web based tools for sharing with other investigators.

Public Health Relevance

Kidney disease is a significant cause of death and disability in patients with SLE. Current treatments have insufficient efficacy and high toxicity. Because SLE patients differ from each other with respect to the patterns of kidney disease we will use several mouse models of SLE nephritis to understand more about the mechanisms for kidney inflammation and remission in different types of kidney disease and use the data obtained to probe information obtained from human SLE kidney biopsies. We will perform gene discovery experiments to identify novel patterns of gene expression that are associated with the various stages of kidney disease and with responses to treatment. Our studies should help us identify new pathogenetic disease mechanisms, to find novel targets for therapeutic intervention and to identify robust biomarkers that will help predict outcomes and responses to therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK085241-03
Application #
8234095
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Flessner, Michael Francis
Project Start
2010-05-13
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
3
Fiscal Year
2012
Total Cost
$534,824
Indirect Cost
$121,711
Name
Feinstein Institute for Medical Research
Department
Type
DUNS #
110565913
City
Manhasset
State
NY
Country
United States
Zip Code
11030
Hodgin, Jeffrey B; Berthier, Celine C; John, Rohan et al. (2014) The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy. PLoS One 9:e103413
Bethunaickan, Ramalingam; Berthier, Celine C; Zhang, Weijia et al. (2014) Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice. Arthritis Rheumatol 66:2246-58
Davidson, Anne (2014) Editorial: autoimmunity to vimentin and lupus nephritis. Arthritis Rheumatol 66:3251-4
Sahu, Ranjit; Bethunaickan, Ramalingam; Singh, Satwinder et al. (2014) Structure and function of renal macrophages and dendritic cells from lupus-prone mice. Arthritis Rheumatol 66:1596-607
Dai, Chao; Wang, Hongyang; Sung, Sun-Sang J et al. (2014) Interferon alpha on NZM2328.Lc1R27: enhancing autoimmunity and immune complex-mediated glomerulonephritis without end stage renal failure. Clin Immunol 154:66-71
Bethunaickan, Ramalingam; Berthier, Celine C; Zhang, Weijia et al. (2013) Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One 8:e77489
Liu, Zheng; Bethunaickan, Ramalingam; Huang, Weiqing et al. (2011) Interferon-? accelerates murine systemic lupus erythematosus in a T cell-dependent manner. Arthritis Rheum 63:219-29
Bethunaickan, Ramalingam; Berthier, Celine C; Ramanujam, Meera et al. (2011) A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 186:4994-5003
Liu, Zheng; Bethunaickan, Ramalingam; Huang, Weiqing et al. (2011) IFN-ýý confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice. J Immunol 187:1506-13
Liu, Zheng; Davidson, Anne (2011) BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res 317:1270-7